transposons and imprinted genes, and enhanced susceptibility to adult chronic diseases. Nutrition 2004;20:63-68. 58 Charlton BG. Is immortality a possibility? A thought experiment concerning the inevitability of senescence due to endogenous parasitism. Perspect Biol Med 1995;39:146-49. 59 Greaves M. Cancer causation: the Darwinian downside of past success? Lancet Oncol 2002;3:244-51. 60 Weiss KM. Is there a paradigm shift in genetics? Lessons from the study of human diseases. Mol Phylogenet Evol 1996;5:259-65. 61 ). One reason cancer must usually be an evolutionary phenomenon is that misbehaving cells are not generally compatible with embryogenesis. This is why we do not inherit a 'cancer' genotype, most cancer-related mutations are cellularly recessive, and loss of heterozygosity or additional mutations at other genes occur somatically. That was at the heart of Kundson's insight (and, in a way, Macfarlane Burnet's earlier 'forbidden clone' hypothesis must have been a factor in Knudson's thinking since it was in the air at the time).
Precursor growths, of which the classic instance were colorectal polyps, were long thought to raise risk at least in part by increasing cell divisions during which subsequent Departments of Anthropology and Biology, Penn State University E-mail: kmw4@psu.edu mutations could occur. That idea became even clearer when it was shown that tumours are clonal and by recent tumour gene expression profiling. The evolution of drug resistance by gene amplification and the ability to metastasize and colonize specific sites also clearly imply evolution. I would quibble with V&B's statement, if I understand it, that the role of selection of mutated cells has not been clearly investigated, because at least in principle this has been a main focus of cancer genetics for many years. But this is minor relative to their main point that not all cellular misbehaviour need be proliferative growth but includes other things like unhealthy norms of reaction. In a time in science that seeks simple (if not simplistic) Darwinian explanations, it is important and quite within the range of normal biology and evolution that not all selection has to do with differential growth.
V&B have added an additional important twist to the story, which should surprise no evolutionary biologist, and they provide some likely examples. The idea that not all mutations are equivalent with respect to response to environments is a direct extension of what is widely known about genotypes among organisms. That the finger points to environment and not just genes is clear, as they argue. I think they should have cited an era of extensive and influential work 20-30 years ago that made this very point (e.g. ref. 9, 10, among a wealth of others) but in the short memory of contemporary science may have largely been forgotten. At the time, Doll and Peto argued from regional variation in cancer prevalence that most causes had to be environmental, but we have a more nuanced understanding of basic cancer biology today. Environment is still important, perhaps paramount for many cancer types, but as V&B say, environments may trigger different alleles differently.
V&B stress alleles that arise somatically. But there must also be considerable differences among populations in the susceptibility alleles they carry, and these can be part of the story by which different people respond differently even to the same environmental triggers. At least some of the variation is undoubtedly heritable. This is implied by data such as the population variation in the mutations and their frequencies in known susceptibility genes like BRCA1/2, and colorectal cancer related genes, not to mention. . . the rather obvious case of skin cancer and pigmentation genetics. And these usually account for only a fraction of the familial (and hence at least partly inherited) risk. There might be some relevance here to the idea of Mendelian randomization as a kind of test, when enough becomes known about putative risk factors that might have differential cellular response.
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Epidemiologists like to live within the space of tractable models, and V&B give some examples. However, for a long time it has been clear that cancer was not a simple 2 or 3 stage process at the gene level even if such models can be statistically fitted to empirical data at the trait level, because both among cells and in susceptibility variation among individuals cancer is genetically more like a quantitative many-locus trait than a simple one. 12, 13 The price of tractability is oversimplification, which is alright if it leads to success, but not if it leads to hopes for unrealistically simple intervention strategies. We know things are much less replicable than such simple mathematical models suggest, through decades of experience mapping cancer and countless other complex traits, which find some culpable genes but account for only a small fraction of the overall genetic risk. Evolution is always with us, and while Darwin showed us the tiger, it is not yet clear even after 150 years whether we have the tiger by the tail or it has us. That these things are not obvious to everyone, at least in general terms, reflects a failure of our educational system, with a short memory and too much technical specialization, which drives out a more nuanced biology of which evolution is a vital part. V&B have done well to lay out many aspects of the reasons why cancer is an evolutionary disease par excellence. One can hope they are wrong about the daunting complexities they raise-but the evidence supports their concerns, and if that is the reality we will simply have to face it.
